➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKinsey
McKesson
Merck
Moodys

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Patent: 8,597,655

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,597,655
Title:Recombinant fusion protein and polynucleotide construct for immunotoxin production
Abstract: The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.
Inventor(s): Barnea; Itay (Yavne, IL), Benhar; Itai (Rehovot, IL), Ben-Yosef; Rahamim (Mevaseret-Zion, IL), Vexler; Akiva (Hod Hasharon, IL)
Assignee: Ramot at Tel-Aviv University Ltd. (Tel Aviv, IL) The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (Tel Aviv, IL) N/A (N/A)
Application Number:13/239,847
Patent Claims:see list of patent claims

Details for Patent 8,597,655

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Ramot at Tel-Aviv University Ltd. (Tel Aviv, IL) The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (Tel Aviv, IL) N/A (N/A) 2027-05-10 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts
Dow
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.